Cend Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors

Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors
proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.

Davidj mazzoCaladrius biosciencesStephen gunnionLisata therapeutics incCend therapeutics

Coronary Microvascular Dysfunction Market in 7MM is expected to witness a major change in the Study Period 2019-2032, estimates DelveInsight |

Coronary Microvascular Dysfunction Market in 7MM is expected to witness a major change in the Study Period 2019-2032, estimates DelveInsight |
medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.

Lisata Therapeutics, Inc (NASDAQ:LSTA) Q3 2023 Earnings Call Transcript

Operator: Welcome to the Lisata Therapeutics Third Quarter 2023 Financial Results and this is a day conference call. Currently, all participants are in a listen-only mode.

United statesDavid mazzoJohn mendittoJames niscoPickleball companiesCorporate communications at lisataLisata therapeutics incExchange commissionBiggest packaging companiesLisata therapeuticsCall transcript novemberLisata therapeutics third quarterVice presidentInvestor relationsCorporate communicationsChief executive officer

Lisata Therapeutics Receives $2 2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program

Lisata Therapeutics Receives $2 2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesDavidj mazzoExchange commissionLisata therapeutics incLisata therapeutics inc john mendittoviceJersey economic development authorityCend therapeutics incNew jersey economic development authorityNew jersey basedChief executive officerPrivate securities litigation reform actCend therapeuticsNasdaq capital marketAnnual reportInc john mendittovice president

Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

The iLSTA Trial is the first study combining LSTA1 with standard-of-care chemotherapy and immunotherapy WARPNINE to provide funding and local trial management BASKING RIDGE, N.J. and. | April 18, 2023

United kingdomWestern australiaMeg croucherJohn mendittoCend therapeutics incExchange commissionLisata therapeutics incCorporate communicationsAndrew deanMedical oncologistChief executive officerExecutive vice presidentChief medical officerPrivate securities litigation reform actCend therapeuticsNasdaq capital market